We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Planned action next month threatens to cause ‘biggest disruption from NHS walkouts so far’
Experiment in Switzerland’s biggest city will assess benefits of regulating supply of the recreational drug
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
UK genomic sequencing group ‘not ruling out’ any options, says chief executive
Companies want incentives to create jobs and stave off competition from China
MHRA chief in talks with watchdogs in Australia, Canada, Singapore and Switzerland to create partnership
Health body says genetic sequences are not definitive and all origin theories, including lab leak, remain on table
After decades caring for people at their most vulnerable, her experience maps the path the UK has taken
Regulators find Danish drugmaker sponsored ‘disguised’ promotional campaign
Chancellor sets sights on 7mn adults who are not in work as campaigners express concerns over medical assessments
With the latest credit for research intensive businesses, the government is picking winners by the back door
Chancellor Jeremy Hunt vows to make Britain the ‘best place in Europe’ for tech companies to invest
Unexpected finding suggests popular sweetener could treat autoimmune conditions such as arthritis and diabetes
Wes Streeting sets out party’s policy to hold care home sector to account over delivery of public sector contracts
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Update to Home Office licence will allow London-listed pharmaceuticals group to pursue supply deals
Despite US blacklistings hampering sales and supplies, the real problem is a dwindling market
UK biotech Awakn licences ‘party drug’ to addiction clinics
Tens of thousands of medics strike in the latest blow to the health service, staff warn of deteriorating conditions and pay
Company’s shares jump after activist investor launches proxy battle
Acquisition price tag will leave investors feeling queasy
US pharma group to pay $229 a share in cash deal that signals rebound in M&A activity
Linklaters, The Bank of England and JPMorgan Chase are making virtual and on-site psychologists available
Scandal spurs questions about quality control at Indian companies and regulatory oversight in poorer countries
Unequal access to jabs in 2021 led to one preventable death every 24 seconds, politicians and activists say
UK Edition
